Loading...
Elevated beta-hydroxybutyric acid with no ketoacidosis in type 2 diabetic patients using sodium-glucose cotransporter-2 inhibitors
Thapa, Simant Singh Lal, Amos Omer, Abdulkadir Trivedi, Nitin
Thapa, Simant Singh
Lal, Amos
Omer, Abdulkadir
Trivedi, Nitin
Citations
Altmetric:
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Letter to the Editor
Publication Date
2019-05-14
Subject Area
Embargo Expiration Date
Link to Full Text
Abstract
SGLT2 inhibitor (SGLT2i) class of medications are known to cause to euglycemic diabetic ketoacidosis (euDKA) as reported in the article by Lin et al. in your esteemed publication about this entity being reported for the first time in Taiwanese population.We wish to share the findings from our center to further expand the spectrum of findings associated with SGLT2i therapy.
Source
J Formos Med Assoc. 2019 May 14. pii: S0929-6646(19)30390-0. doi: 10.1016/j.jfma.2019.04.021. [Epub ahead of print] Link to article on publisher's site
Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
10.1016/j.jfma.2019.04.021
Permanent Link to this Item
PubMed ID
31101495
Other Identifiers
Notes
Funding and Acknowledgements
Corresponding Author
Related Resources
Related Resources
Repository Citation
Rights
Copyright 2019, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).